Pablo Legorreta, Co-founder and Chief Executive Officer
Mr. Legorreta co-founded Royalty Pharma in 1996, after founding and managing two ‘proof of principle’ investment vehicles that invested in Neupogen and ReoPro royalty interests. Prior to founding these funds, Mr. Legorreta spent ten years at Lazard Freres, providing cross-border merger and acquisition and corporate finance advisory services to U.S. and European corporations. Mr. Legorreta currently serves as a Director of Giuliani S.p.A and Hottinger American Investors Fund. He received a degree in Industrial Engineering from Universidad Iberoamericana.

Rory Riggs, Co-founder and Chairman
Mr. Riggs co-founded Royalty Pharma in 1996 and assumed the role of Chairman in 2003. Mr. Riggs is also the managing member of Balfour Venture Partners, an investment advisor focused on mid-stage healthcare companies. From 1996 to 2000, he was President of Biomatrix, a New York stock exchange listed biopharmaceutical company. From 1991 to 1995, Mr. Riggs served as President and CEO of RF&P Corporation, an investment company owned by the State of Virginia Retirement system. Prior to that, Mr. Riggs spent ten years as a member of PaineWebber’s mergers and acquisitions department. Mr. Riggs graduated from Middlebury College and holds an M.B.A. degree from Columbia University.

Susannah Gray, Executive Vice President and Chief Financial Officer
Ms. Gray joined Royalty Pharma in January 2005 after a 14 year career in investment banking. From 2002 to 2004, Ms. Gray was a managing director and the senior analyst covering the healthcare sector for CIBC World Market's high yield group. Prior to joining CIBC World Markets, she worked in a similar capacity at Merrill Lynch. Ms. Gray joined Merrill Lynch in April 1999 after nine years at Chase Securities (a predecessor of JP Morgan), working in various capacities within the high yield and the structured finance groups. Ms. Gray received a B.A. with honors from Wesleyan University and holds an M.B.A. degree from Columbia University.

Michael Herman, Senior Vice President, Royalty Investments
Mr. Herman joined Royalty Pharma in 1996. From 1994 to 1996, Mr. Herman consulted for several financial concerns, including Apollo Advisors, Société Géneralé, and International Technology Investment Managers, the general partner of the “proof of principle” funds. From 1991 to 1994, Mr. Herman was an analyst in the fixed income division of Lehman Brothers. Mr. Herman received a B.A. with honors from the University of Michigan.

Alexander Kwit, Executive Vice President and General Counsel
Mr. Kwit joined Royalty Pharma in 2001. Prior to joining Royalty Pharma, from 2000 to 2001, he served as general counsel for KPE, a digital and media entertainment company. From 1996 to 2000, Mr. Kwit was an associate with Davis, Polk and Wardwell, a New York-based law firm, where he specialized in mergers and acquisitions and securities law. Mr. Kwit received a B.A. from Duke University, where he was elected to Phi Beta Kappa and holds a J.D degree from Columbia University, where he was a Harlan Fiske Stone Scholar. He has been a member of the New York State Bar Association since 1997.